A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human
CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To obtain a
preliminary indication of the antiviral effects of rCD4 in patients with AIDS and ARC. To
measure steady state serum levels of rCD4 following continuous infusion therapy.